Anti-Rheumatic Drugs as Potential Anti-inflammatory, Immunomodulatory Agents against COVID-19: A Systematic Review

Reza Sinaei1,2*, Sara Pezeshki1,3*, Ali Asadipour4, Reza Shiari5, Roya Sinaei1, Ali Sinaei1

1Department of Pediatrics, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
2Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.
3Department of Internal Medicine, Kerman University of Medical Sciences, Kerman, Iran.
4Pharmaceutical Sciences and Cosmetic Products Research Center, Kerman University of Medical Sciences, Kerman, Iran.
5Department of Pediatric Rheumatology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
6School of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.

Abstract

Background: The effective responses of both innate and adaptive immunity are crucial in combating novel coronavirus-2 infection. An excessive response may lead to cytokine storm, which is a challenging problem in therapeutic strategies.

Methods: A systematic review was carried out by searching Ovid MEDLINE, PubMed, Google Scholar, and Cochrane library databases from inception, for anti-inflammatory and immunomodulatory drugs against coronavirus disease 2019 (COVID-19).

Results: The results of the effectiveness of Hydroxychloroquine are just like a sinusoidal diagram and in a state of ambiguity. Thalidomide was effective in some cases but has not yet been proven. Low-dose Corticosteroids may be effective in the early stages of the illness as a bridge. There is no evidence of benefits or adverse outcomes for the use of non-steroidal anti-inflammatory drugs and Cyclosporine-A. In some critically ill patients, Interleukin-6 (IL-6) and IL-1 blockers and to some extent, Tumor-Necrosis-Factor-a and Janus-Kinase inhibitors are useful. Finally, high-dose intravenous immunoglobulin reversed the deterioration of patients in most trials.

Conclusion: One strategy behind the treatments for COVID-19 is based on breaking the cytokine storm. Although avoiding the suppression of anti-viral immunity is crucial by choosing the weaker and more selective anti-inflammatory agents, some strategies are kept for hyper-inflammatory situations. Scheduling of treatment is also important. Although low-dose steroids may be effective in the early stages of the illness, "Tocilizumab" is more effective in severe situations, when the IL-6 level is high and other drugs are ineffective. Therefore, consideration should be given to each patient separately.

Introduction

The emergence of the novel coronavirus, which causes severe respiratory infections, has become a global health concern. About 80% of patients experience mild to moderate disease and the fatality rate is about 2.3%.1 Excessive immune responses to infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been incriminated in both respiratory distress and multi-organ failure that is seen more in some patients.2 Considering both the severity of the disease and the response capacity of health systems is important in the management strategies. In this setting, secondary bacterial infections should be noted.1,3 Due to the rapid spread of COVID-19 and high mortality of the severe disease, understanding the disease immunopathogenesis and inflammatory response is obligatory. According to the evidence, Angiotensin-Converting Enzyme-2 (ACE-2) is the enzyme that acts as the receptor, allowing SARS-CoV-2 to enter the cells.4 After the recognition of the virus by Toll-like Receptors (TLR), signaling pathways activate nuclear factor (NF)-kB and then pro-inflammatory cytokines. The initiation of immune response is through some cytokines such as IL-1β and TNFα.1,3 A sizeable number of patients develop a severe hyper immune response characterized by a cytokine storm.6 Just like hemophagocytic lymphohistiocytosis (sHLH) and macrophage activated syndrome (MAS), there is a cytokine profile that is also responsible for the COVID-19 severity.7 Hyper inflammatory markers including elevated

*Corresponding Authors: Sara Pezeshki, Email: s.pezeshki@kmu.ac.ir; sarapezeshki83@gmail.com
©2021 The Author(s). This is an open access article and applies the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited.
IL-6 and ferritin are predictors of fatality. Caricchio et al. developed new predictive criteria for COVID-19 cytokine storm, met when patients meet all the entry criteria (signs/symptoms of COVID-19, positive molecular test, ground-glass opacity, ferritin>250 ng/ml, C-reactive protein (CRP)>4.6 mg/dl) and one variable from each cluster. The first cluster included decreased levels of albumin, lymphopenia, along with increased absolute neutrophil count. The second cluster included the increased levels of both alanine and aspartate aminotransferases, D-dimers, Lactate dehydrogenase, and Troponin-I. The third cluster included the decreased anion gap, and increased levels of chloride, potassium, and blood urea nitrogen: creatinine ratio. Although these criteria need further validation, they can be readily used in practice to determine the need for an early therapeutic regimen, blocking the hyper-inflammatory response, and thereby reducing mortality. However, several potential anti-inflammatory and immunomodulatory agents are candidates. Although there have been no significant relapses of rheumatic disease in SARS-CoV-2 infection, the relationship between these agents and viral infections is very complex and even a simple scenario of fever and arthritis may be challenging to differentiate between infections and reactive arthritis.¹⁻³,¹¹¹

These, along with the historical background of using the rheumatic drugs in infectious diseases,¹ justify the hypothesis of their use in COVID-19. However, a variety of both biological and non-biological agents are candidates. Blocking the inflammatory cascade by some traditional or milder anti-inflammatory or immunomodulatory drugs such as anti-malarial agents, or stronger suppression of hyper-inflammatory states in some situations by IL or TNFα inhibition is of great importance.

This review focuses on the effects of some proposed anti-inflammatory and immunomodulatory drugs, noting some of their immunosuppressive effects.

Methods
Study protocol
We aimed to include all scientific papers, which had evaluated the anti-inflammatory and immunomodulatory agents against COVID-19, without limitations. The PRISMA guideline for a systematic review was followed for study design, search protocol, screening, and reporting (Figure 1). Searching databases, selecting studies, evaluating the quality of studies, and extracting data were done by two researchers. Whenever there was a discrepancy between them, the subject was consulted with and considered by a third reviewer. The protocol is available at PROSPERO (CRD42020221700).

Inclusion and exclusion criteria
Inclusion criteria for the studies were as follows: 1. RCTs, case series, case-controllers, and cohort studies, investigating the effect of anti-inflammatory, immunomodulatory agents in the management of COVID-19 (Due to paucity of information especially in some class drugs, all scientific articles even case reports were included.); 2. Articles in which the study population were more than 18 years with both confirmed and suspected COVID-19. We excluded articles without complete information, with low quality, letters to the editor without case presentation, and public health agencies or institutes recommendations, alongside expert consensus, because of their frequent renewal. In addition, we did not include ongoing clinical trials and reviews. In vitro studies were cited in the text only to supplement insufficient information. We excluded trials evaluating traditional Chinese medicines and non-immunomodulatory drugs. The planned primary outcomes, which were selected based on their clinical usefulness, included time to hospital stay and severity characterized by requirements for invasive mechanical ventilation. Secondary outcomes included time to clinical improvements, the adverse events related to the treatment, overall mortality, and 28-day mortality.

Information databases and search strategy
A systematic review was carried out by searching OVID MEDLINE, PUBMED, Google Scholar, and Cochrane library databases from inception up to August 2, 2020. No language and status (abstract or full text) limitations were imposed. Keywords selection was done based on Mesh terms using “OR” and “AND” operators and included the following terms used in titles, abstracts and keywords: [“COVID-19”, OR “SARS-CoV-2 infection”, OR “Coronavirus”, OR “2019-nCoV infection”, OR “2019-nCoV disease”, OR “2019 novel coronavirus disease”, OR “COVID-19 drug treatment”, OR “Middle East Respiratory Syndrome Coronavirus”, OR “SARS Virus”, OR “severe acute respiratory syndrome”], AND [“anti-inflammatory agents”, OR “Immunomodulation”, OR “antiviral agents”, OR “Cytokines”, OR “Acute-Phase Reaction”, OR “Pharmaceutical Preparations”, OR “Therapeutics”, OR “Antimalarial”, OR “Chloroquine (CQ)”, “Hydroxychloroquine (HCQ)”, OR “Anti-Inflammatory Agents, OR Non-Steroidal”, OR “Glucocorticoids”, OR “Thalidomide”, OR “Cyclosporine”, OR “Tumor Necrosis Factor-alpha”, OR “Tocilizumab”, OR “Sarilumab”, OR “interleukin-6”, OR “anti-IL-6”, OR “Janus kinase inhibitors”, OR “Interleukin 1 Receptor Antagonist Protein”, OR “Interleukin-1”, OR “Canakinumab” OR “Immunoglobulin, Intravenous”, and some other non-Mesh terms [All Fields] of “IVIG”, OR “IL-6 blocker”, OR “NSAID”]. Correlated references of the selected studies were searched manually.

Selection of studies and data extraction
Two authors and one highly experienced librarian extracted articles independently by providing information on the efficacy and safety of anti-inflammatory and immunomodulatory drugs in COVID-19. The first step included the screening of titles and abstracts of all retrieved references and then cross-checking the results. Due to rarity, we increased the references using an
additive snowballing technique (n=121). The information extracted from the articles were summarized in the data extraction form as first author, publication date, country of study, journal, type of study, and PICO as population, type of interventions, number of people in the control and intervention groups, mean age of patients in each group and outcomes. The EndNote X5 Resources Management Software was utilized for categorizing, studying the titles and abstracts, and identifying duplicate cases. When studies did not report an effect size (HR, OR, or RR) for outcomes including mortality risk, we used the number of deaths per group. The quality of the included articles was assessed using the Joanna Briggs Institute (JBI) critical appraisal tools. The various papers were evaluated by two independent authors assessing the trustworthiness, relevance, and results irrespective of their risk of bias rating.

**Assessment of risk of bias in included studies**
National heart, lung, and blood institute (NHLBI) tool was used to assess the risk of bias for observational studies, case series, and each eligible trial illustrated in Tables S1-S8 in supplementary data. The quality was considered as rates of good, fair, and poor if they fulfilled 60-100%, 50-59%, and less than 49% of the tool items, respectively. The included case reports were considered poor due to the low sample sizes of the case series.

**Statistical analysis**
Due to heterogeneity between the results and paucity of papers, multiple errors in several systematic reviews seem relevant to the subject resulting in not feasibility to perform a suitable meta-analysis to combine the results.

**Results**
The initial search identified 1810 results. Following the removal of duplications, screening and full-text review, of which a total of 108 relevant articles deemed suitable were included for 10 drug groups separately. Tables S1-S8 in supplementary data, summarize the identified results of the articles' characteristics and outcomes. In vitro articles were only included in the text as supplementary issues, but not included in the tables. More relevant included articles in these supplementary tables were 21-46 in HCQ, and CQ group (N=26), 51-67 in CS group (N=17), 78-80 in NSAID group (N=3), 66 in thalidomide group (N=1), 56, 62, 65, 103-105 in IVIG group (N=6) as non-biologic disease-modifying anti-rheumatic drugs, and 107, 118-150 in IL-6 blockers (N=34), 152-159, 161-162 in IL-1 blockers (N=10), 164-172, 174-176 in JAK and Tyrosine kinase inhibitors group (N=12), and finally 180-182 in TNF blocker group (N=3), as biologic categories. Risk of bias assessment of the retrieved studies identified several limitations and highlighted a number of biases. Following a formal risk of bias assessment, 40 (37%), 47 (43.5%), and 21 (19.5%) studies were rated as good, fair, and poor, respectively.
Non-biologic disease-modifying anti-rheumatic drugs
Antimalarial agents (HCQ)

Both immunomodulatory agents have been used in auto-inflammatory and Rheumatic diseases (e.g. Lupus, Rheumatoid arthritis (RA)). They inhibit chemotaxis, nitric oxide production, and phagocytosis. Moreover, they may antagonize the action of prostaglandins (PGs), interfere with the production of IL-6, IL-1, INFγ, and TNFα, and have antagonistic effects upon TLR7/9.\textsuperscript{13-14}

In vitro studies suggested that HCQ inhibits SARS-CoV2 replication.\textsuperscript{15} These broad-spectrum effects occur by both increasing endosomal PH, blocking replication, as well as interfering with glycosylation of ACE-2 receptors of SARS-CoV. Moreover, the effects of CQ were found during the post-entry stages via inhibition of viraPLpro.\textsuperscript{16,17}

One study revealed that CQ can inhibit the novel-CoV-2 replication with a half-maximal effective concentration (EC\textsubscript{50}) of 1.13 μM and a half-cytotoxic concentration (CC\textsubscript{50}) greater than 100 μM.\textsuperscript{18} Liu et al.\textsuperscript{19} found a similar CC\textsubscript{50} for two drugs, but EC50 was more for HCQ than CQ. Furthermore, Yao et al.\textsuperscript{20} found that HCQ (EC\textsubscript{50}=0.72 μM) is more potent than CQ (EC\textsubscript{50}=5.4 μM) in virus inhibition. A prospective cohort of 48 moderate COVID-19 cases was conducted. CQ (1000 mg on day one, then 500 mg/ daily for nine days; n=18), HCQ (200 mg BID for 10 days; n=12) had beneficial effects on clinical recovery, duration of hospitalization, and Lung CT scan findings in moderate illnesses.\textsuperscript{21} Several other cohorts revealed similar beneficial results with Hydroxy-(CQ)\textsuperscript{22-25} alone or in combination with azithromycin.\textsuperscript{26,20}

Yu et al.\textsuperscript{23} found that HCQ in 568 critically ill COVID-19 patients is significantly associated with lower mortality via attenuation of the inflammatory cytokine storm. Several other studies showed that HCQ alone or in combination with azithromycin reduced mortality.\textsuperscript{29,30} However, in a retrospective analysis of 807 laboratory-confirmed patients with COVID-19 in the US, HCQ with (n=214) or without (n=198) azithromycin no significant reduction in mortality or the need for mechanical ventilation was identified although an association of increased overall mortality was observed in those treated with HCQ alone.\textsuperscript{28} In a retrospective multicenter cohort of 1438 hospitalized COVID-19 patients, those who received HCQ with or without azithromycin were similar without significant differences in mortality.\textsuperscript{31} Coinciding with no beneficial effects in other observational studies in both moderate and severe illness courses,\textsuperscript{23,32-38} and even mild to moderate inpatients,\textsuperscript{39} as well as outpatient recipients.\textsuperscript{40}

In contrast, in a cohort of 63 hospitalized CoV-2 patients, HCQ was associated with an increased need for escalation of respiratory support.\textsuperscript{41} However, most studies had a moderate risk of bias due to their small sample sizes and methodological process.

A French parallel, double-blind, randomized trial suggested that a higher dosage of CQ is not recommended for critically ill patients, especially in combination with azithromycin or oseltamivir.\textsuperscript{42} Some controlled studies utilized 800-1200 mg,\textsuperscript{32,35,41,44} as loading dose, and a doses of 200-800 mg/day\textsuperscript{25,26,34,37,42,} as maintenance therapy from 5 days\textsuperscript{34-46} to 2-3 weeks.\textsuperscript{46}

Anyway, HCQ within 4 days post-exposure prophylaxis of 821 participants revealed no beneficial effect.\textsuperscript{46}

Systemic corticosteroids (CS)

CSs reduce inflammation by inhibiting arachidonic acid, IL1, TNFα, and NF-κB. Their effects on the immune system are mediated mainly via T cells.\textsuperscript{13}

Studies: No in vitro studies were found on cytopathic effects of them alone against SARS-COV. Several studies including animal models have shown that CS for treatment of SARS- CoVs were associated with prolonged viremia and worse outcomes.\textsuperscript{47,48} In contrast, high dose CS in the early stage of SARS-CoV had beneficial effects in previous cohorts.\textsuperscript{49} Furthermore, in a retrospective cohort of patients with SARS-CoV and sepsis, CS in 147 of 249 noncritical patients, reduced mortality and the duration of admission, whereas 121 of 152 critical patients received CS and 25 patients died.\textsuperscript{50}

In several studies, CSs were significantly associated with lower duration of admission in COVID-19 patients.\textsuperscript{51-53} Wang et al.\textsuperscript{54} reported 46 patients with COVID-19 whose symptoms and chest CT-scan results were improved with 5 to 7 days administration of methylprednisolone.\textsuperscript{44} In a case series of 15 COVID-19 patients, CS decreased the need for vasopressors and improved the oxygenation, CRP levels, and reduced the hospital stay.\textsuperscript{54} Moreover, in a retrospective cohort of COVID-19 patients, CSs were associated with a lower mortality rate. The authors found no association between therapy and outcomes in patients without ARDS.\textsuperscript{55} Zhou et al.\textsuperscript{56} reported that a moderate dose of CS plus Intravenous Immunoglobulin (IVIG) significantly reduced lung injury.In addition, an early short course of methylprednisolone in moderate to severe cases of COVID-19 reduced the escalation of care and improved clinical outcomes in two studies.\textsuperscript{57,58} Recently, in a randomized, controlled, open-label trial of COVID-19 hospitalized patients, dexamethasone 6 mg/day improved clinical outcomes in two studies.\textsuperscript{57,58} In a case series of 101 confirmed COVID-19 patients, a single-dose pulse of methylprednisolone had no apparent negative impact on virus removal, while effectively stopped the inflammatory cascade.\textsuperscript{60} Also, in a recent observational study including 1806 hospitalized COVID-19 patients, early use of CS in 140 patients was not associated with mortality or mechanical ventilation, especially in those whose CRP levels were more than 20 mg/dl.\textsuperscript{61} Contrarily, a cohort of 416 COVID-19 patients revealed that CS increased the mortality rate and appeared to be useful only in the cases with lymphopenia.\textsuperscript{62} Moreover, in a Japanese case series of 7 patients with COVID-19, high dose, short term methylprednisolone enabled extubation of the patients within 7 days.\textsuperscript{63}

In a case series of 24 COVID-19 patients, three patients with asthma who had received CS before admission...
represented with severe symptoms requiring mechanical ventilation. In addition, there is evidence of successful treatment with CS in combination with IVIG, thalidomide, or standard of care in some reports.65-67

Non-steroidal Anti-inflammatory Drugs (NSAIDs)
NSAID as cyclooxygenase (cox1/cox2) inhibitors are used clinically for their anti-inflammatory, analgesic, and anti-pyretic properties. COX1 provides PGs for housekeeping, while COX2 is upregulated at sites of inflammation by IL-1, TNFa, endotoxins, and growth factors.13 There is a lack of in vitro studies on the use of NSAID on COVID-19. An in vitro study revealed that ibuprofen and naproxen were inhibited the Ab production at pharmacologic doses.68 A dramatic antiviral effect of Indomethacin was found in a model of feline coronavirus infected cells, as well against Canine- CoV as, by inhibiting virus replication and protecting the host cell from virus-induced damage.69 Antiviral efficacy of indomethacin was determined by evaluating virus tilters in CoV-infected dogs, and also in one human study.70-71 Concerns about ibuprofen seem to be due to the increase in an over expression of ACE2 in diabetic rats and diabetic patients.72-73 Therefore, this effect may worsen the clinical course and even susceptibility to COVID-19 infection theoretically.74 Also, concerns about ibuprofen invigorated from an unpublished idea of a French physician who claimed that four patients with COVID-19 developed a severe form of the illness after using NSAIDs.75 Several studies suggest that the use of NSAIDs before or during admission with pneumonia including viral infection may be associated with an increased risk of empyema.75,76

A clinical review of chemotherapeutic strategy for severe COVID-19 pneumonia pointed out that celecoxib and thalidomide can modulate IkBa degradation and phosphorylation.77 In a retrospective cohort of 403 confirmed cases of COVID-19, ibuprofen was not associated with worse clinical outcomes.78 The association between ibuprofen and severity among 1872 patients with COVID-19 was insignificant, albeit with a trend towards increased disease severity risk.79 In contrast, in another study, NSAID was associated with worse outcomes among hospitalized users.80

Thalidomide
This major teratogen agent has been used due to antiemetic, analgesic, anxiolytic, and sedative properties or in the template of some malignancies, autoimmune, and infectious diseases.13 It suppresses activated NF-kB that promotes TNFa production. Furthermore, it inhibits phagocytosis, chemotaxis, and reduces the expression of TNFa, IL-1B, and IL-6 mRNA.13,81

One study revealed that thalidomide decreases the expression of IL-1B and IL-6 in human epithelial cells; therefore, it may help prevent emphysema.82 It can reduce the HIV replication by TNFa in human macrophages in vitro.83 Moreover, it may express immunomodulatory effects in cell cultures, especially in combination with celecoxib, and suppress the production of TNFa and IL-8 via inhibition of NF-kB.77 Anti-inflammatory effects of thalidomide in an animal model showed that it decreased the production of IL-1B, IL-6, TNFa, and TGFβ.84 It attenuates inflammation, oxidative stress, and pulmonary fibrosis in mice lungs.85 Also, antibiotic effects against bleomycin-induced pulmonary fibrosis were seen in rats.86 In H1N1 influenza-induced pulmonary injury in mice thalidomide dramatically inhibited the activated P- NF-kB p6 and reduced the inflammation.87 However, the beneficial effects of thalidomide (100mg/day) in combination with a low dose of CS were shown in a 45-year-old woman with COVID-19.88

Cyclosporine (CsA)
CsA has had a major impact on the prevention of solid organ transplant rejection. Also, it has potential effects on immunologically mediated diseases. CsA inhibits calcineurin, therefore, it inhibits the early phase of T cell activation and IL2-4, IL15, and INFγ production, and may modulate anti-inflammatory effects by inhibiting NF-kB.13

Although Low micromolar, non-cytotoxic concentration of CsA strongly affected the replication of some viruses in cell culture, more concentration is needed to block coronaviruses, suggesting that coronaviruses are less sensitive to CsA treatment.84 CsA is considered as an interaction partner of SARS-CoV N-protein.89 It might exert its effect by inhibiting cyclophilin or even direct inhibitory effect on virus function.90 It has been reported to inhibit the replication of HIV, vesicular stomatitis virus (VSV), HCV, and influenza-A.91-94 but in vivo studies on CoVs family especially CoV-2 infection are required. The patients who meet the ILH criteria may benefit from the use of related chemotherapeutic agents like CsA.7

Biological anti-rheumatic drugs

IVIG
Intravenous immunoglobulin (IVIG) is prepared from pooled human plasma. It is mainly administered for autoimmune, auto inflammatory conditions and has been used as an anti-infectious agent. Its Fab-mediated functions include suppression of cytokines, auto antibodies and complements, targeting of specific immune cell surface receptors, expression of regulatory T-cells by induction of COX2 dependent PGE2 in dendritic cells, and blockade of leukocyte adhesion molecule binding. Moreover, some FC-dependent activities include blockade of fragment crystallizable y-receptor (FcγR), the neonatal Fc receptor (FcRn) and immunomodulation by salivated IgG.95

IVIG has been used as an anti-infective in experimental models.96-97 Pyrc et al.98 showed that human sera from healthy people and IVIG can neutralize H-CoV-NL63. In another study, IVIG obtained from donors with higher Abs against RSV had significant potential to improve
the outcome of respiratory syncytial virus infection in immunocompromised subjects, not only by controlling viral replication but also by reducing damage to the lungs. A murine model of induced colitis revealed that IVIG reduced intestinal inflammation by suppression of IL-6, also inhibited the growth of some microorganisms in the gut of mice. In previous studies on SARS and MERS, IVIG exhibited various clinical benefits. The clinical data of 10 patients with COVID-19 receiving short-term corticosteroid (160 mg/day) plus IVIG (20 gr/day) were collected. This combination significantly reduced SpO2 and lung lesions and normalized ALC and CRP levels. Furthermore, the administration of the high-dose IVIG on 3 patients with COVID-19, just at the time of initiation of respiratory distress, significantly improved clinical symptoms and radiological findings. Similarly, two retrospective cohort indicated beneficial effects when high-dose IVIG was administrated early in the critical COVID-19 patients.

Contrairement, in a cohort of 416 COVID-19 patients who received CS and concurrent IVIG, the use of IVIG was not a rescuer. described a couple who were successfully treated with methylprednisolone and IVIG. However, the efficacy of IVIG would be better if the immune IgG Abs was specific against COVID-19 by boosting the immune response in newly infected patients, especially when it is collected from patients recovered from COVID-19 in the same city or surrounding area.

**IL-6 blockers**

Tocilizumab (TCZ) and sarilumab are humanized monoclonal antibodies to the IL-6 receptor that can inhibit intracellular signaling originating from IL-6. They are administered in some auto-inflammatory and autoimmune diseases. Since IL-6 and granulocyte-macrophage colony-stimulating factor (GM-CSF) are key cytokines, which may result in lung injury, they might play a therapeutic role in severe and critical COVID-19. Apart from the anti-inflammatory role of TCZ, it might be hypothesized that the beneficial effects of TCZ on the coagulation abnormalities associated to COVID-19 are also relevant. The findings suggest that the overexpression of IL-6 and IL-2R is useful for estimating the severity of COVID-19. Animal models showed an association between IL-6 level and SARS-CoV severity. However, there was no significant difference in cytokine levels in the presence of SARS symptoms in 14 adult CoV patients. This discrepancy has been justified in some studies with delayed inflammation. imbalance between IL-6 and IL-10, or the presence of another mechanism such as gamma interferon-related cytokine storm. At least, it has been shown that four potential CoV therapeutic targets (ADAM17, DUSP1, P38MAPK, GU-rich ssRNA) are related to IL-6 regulator.

In a cohort of 28 patients with severe COVID-19 who were treated with sarilumab and 28 contemporary patients receiving standard of care alone; on day 28, overall clinical improvement and mortality were not significantly different between the two groups. Sarilumab was associated with faster recovery in a subset of patients showing minor lung consolidation at baseline (P=0.01). in a case series of 15 patients with COVID-19 treated with sarilumab, revealed a rapid improvement in respiratory parameters and a reduction in CRP levels in 67%, while 34% of patients died. In a clinical series of eight patients, early treatment with sarilumab led to progressive reduction in CRP and earlier discharge. Similarly, the investigation of 53 patients with severe SARS-CoV-2-related pneumonia in both medical ward and ICU who received sarilumab in addition to other drugs revealed beneficial effects. A prospective case series was performed on 63 patients with COVID-19. TCZ decreased fever, PaO2/FiO2, CRP, ferritin, D-dimer, ALC, and the chance of mortality within six days of treatment. Similarly, in a prospective series of 100 consecutive patients admitted with COVID-19 in Italy, the response to TCZ was rapid, sustained, and associated with significant clinical improvements. Several other studies showed the beneficial effects of TCZ in the reduction of both clinical symptoms and inflammatory markers, emphasizing on reduction of the mortality.

In contrast, in a retrospective analysis of 112 severe COVID-19 patients in Italy, TCZ did not reduce ICU admission or mortality rate among 21 patients. Also, in a retrospective cohort of 65 patients with severe COVID-19, while 32 patients were treated with TCZ; on day 28 the clinical findings and mortality rate were not statistically different between groups. A new trial as COVACTA, which was conducted by Roche, did not meet its primary endpoint of improved clinical status.

In a retrospective analysis of 457 COVID-19 patients, hyperglycemia had negative impacts on TCZ therapy in both diabetic and non-diabetic patients. Several beneficial effects of TCZ have been reported in case reports of COVID-19 patients, with or without underlying diseases. Conversely, two cases of COVID-19 induced CRS with elevated IL-6 levels and progression to HLH developed poor outcomes despite TCZ treatment.

In a 57-year-old woman with systemic sclerosis who had developed COVID-19, the treatment with TCZ led to good control of both scleroderma and arthritis. Four weeks after the last TCZ infusion, the patients presented with COVID-19. Albeit, this case presented with mild symptoms that may be due to the prophylactic effects of TCZ.

**IL-1 blockade**

Anakinra is a human recombinant form of IL-1Ra. It prevents the interaction of the receptor with IL-1 and subsequent signaling. Thus, it is used in RA, some auto-
The Rheumatic Drugs against COVID-19

inflammatory diseases (e.g., systemic juvenile idiopathic arthritis (sJIA), cryopyrin-associated periodic syndrome (CAPS)), and HLH. The nCoV might be bind to TLRs which activate the production of pro-IL-1 that mediates the inflammation of lungs, fever, and fibrosis. Although one study showed no difference in IL-1β levels in patients with COVID-19 in any severity and the general population, one animal model has shown beneficial results for an IL-1 receptor antagonist in rats. A small prospective cohort compares outcomes in 52 consecutive patients with COVID-19 treated with anakinra, and 44 historical controls showed that Anakinra for 7 days reduced both the need for invasive MV and mortality. Also, in a retrospective cohort of 29 moderate to severe COVID-19 patients, only the high dose of anakinra (5 mg/kg. IV twice a day) was effective, with a reduction in CRP and a progressive improvement in respiratory function. Other small case series and case reports have reported anecdotal evidence of improvement in outcomes. In a retrospective analysis of ten patients with COVID-19, and respiratory failure, canakinumab, a human monoclonal Ab against IL-1β, 300 mg. SQ. was safe, and associated with a rapid reduction in the inflammatory response and oxygen requirement. Overall, large studies are needed to evaluate the efficacy and safety of anakinra, as targeted therapy. To date, due to promising results, we suggest that only in the situation of the inflammatory storm IL-6 is not high or in HLH / macrophage activation syndrome.

JAK inhibitors

The therapeutic inhibition aspects of intracellular Janus kinase/ signal transducer and activator of transcription (JAK-STAT) pathway have yielded promising results in many systemic (e.g. RA), cancerous, and cutaneous diseases. Baricitinib that selectively inhibits the JAK1/2 has potentially beneficial effects on reducing both viral entry via receptors and also inflammation in COVID-19 patients. In a prospective, multicenter randomized clinical trial revealed the beneficial effects of ruxolitinib in CT-Scan improvement (P=0.049), faster clinical improvement, and a good profile of safety. Giudice et al. revealed a significant improvement in respiratory symptoms and radiographic lesions and a marked decrease in D-dimer levels with ruxolitinib. Baricitinib had several significant effects on both primary and secondary end points of 113 patients with moderate COVID-19-related pneumonia. A pilot study of 12 hospitalized patients with moderate COVID-19 was conducted. In the baricitinib-treated group, all clinical characteristics and respiratory functions improved, and CRP levels decreased at week 1 and 2 compared to the baseline. Another retrospective cohort analysis was carried out on 105 consequent patients with severe COVID-19. Fourteen patients received ruxolitinib due to an inflammatory score (CIS) of 10 or more out of 16 points. A total of 12 achieved a significant reduction of CIS, on day 7 with sustained clinical improvement in 11 cases, without prominent side effects. A prospective case series of 86 patients involved with immune-mediated inflammatory diseases (e.g. RA, psoriasis) who were receiving anti-cytokine biologics and other immunomodulatory agents were conducted when developed COVID-19. Despite the small sample size, the baseline use of biologics and JAK inhibitors were not associated with worse outcomes. Another cohort revealed that baricitinib demonstrated a marked reduction in serum levels of IL-6, IL-1β, and TNFα, rapid recovery in T and B cell frequencies, and an increased antibody production against SARS-CoV-2 spike protein. In a small cohort of 15 patients with COVID-19, baricitinib plus HCQ was associated with recovery in 11 cases. Interestingly, sibulinin as a direct inhibitor of STAT3 has been noted as a dual targeting of host CRS and virus replication. In addition, several beneficial effects of JAK inhibitors have been reported in case reports of COVID-19 patients. A favorable course of COVID-19 was observed in an 87-year-old woman, despite the underlying RA, while she received baricitinib from one year before. This allows speculating that baricitinib had a positive impact on the outcome.

TNFα inhibitors

This group (e.g., etanercept) has been now proven in the treatment of some inflammatory and autoimmune conditions (e.g., inflammatory bowel disease). These inhibitors produced a dramatic reduction of overall illness severity of virus-specific lung immunopathology in mice without interfering with viral clearance. Etanercept has been reported to be effective for the treatment of a non-infectious pulmonary syndrome like SARS pneumonia in one report. In contrast, etanercept alone was not sufficient to ameliorate the disease in the virus-endotoxin mediated model of respiratory disease in pigs. Several studies reported that the use of anti-TNFα prior to COVID-19 infection was not associated with a severe evolution of the COVID-19.

Discussion

All previous studies have some limitations. Unlike preliminary studies, HCQ was associated with no gross effects on the need for respiratory support. Most studies revealed no significant differences in mortality among hospitalized patients with severe illness. Nevertheless, for historical reasons alongside scattered experiences of clinical benefits, the authors suggest using these drugs in early phases or post-exposure conditions. In some studies, H (CQ) had some beneficial effects on clinical recovery, duration of hospitalization, lung CT-Scan findings in moderate illnesses, and even mortality among patients with severe illness. Although CS administration is questionable due to the potential inhibition of viral clearance, increase in the duration of viremia, and some evidence of disease progression, there is increasing evidence of beneficial effects. CS may be beneficial in the early acute phase of...
illness, especially in low doses. Although its use in severe septic shock is doubtful, it may be more useful in HLH and hyper-inflammatory storm in an adequate time. At this time, there is no evidence for or against the use of NSAIDs in COVID-19 patients. Using NSAIDs to confront the virus function and replication is not logical when we have more effective and acceptable drugs. Additionally, thalidomide may shed new light on an adjuvant treatment strategy due to its potentially anti-viral effects, but there are inconsiderable articles regarding its effectiveness. It may be effective as a subsidiary treatment strategy, especially in combination with low-dose CS. Briefly, thalidomide in addition to its ability to inhibit cytokine surge, and immunomodulation effects, could help patients to reduce oxygen consumption, and relieve gastrointestinal symptoms. Also, we cannot suggest CsA as a first-line therapeutic agent, but it should be noted that it can be prescribed in HLH as a potentially effective drug. IVIG seems to be a golden repurposing drug in deteriorating patients, where it can be used at least as a bridge therapy. Patients might not receive much benefit when systemic damage has already taken place. It acts not only by controlling viral replication but also by reducing damage to the lungs. However, it remains in critical cases, just in the early stages of deteriorating. Generally, despite the recent Phase-III COVATA fail consequences, the results are promising and TCZ has been used especially on severe and critical cases with beneficial effects. Since the peak level of IL-6 is associated with the severity of pulmonary complications, TCZ and sarilumab can be used in the early stages of the inflammatory storm, where other drugs are ineffective. Large studies are needed to evaluate the efficacy and safety of IL-1 and TNFα blockade as targeted therapy. At this time, we suggest anakinra, as a promising repurposing strategy only in the situation of an inflammatory storm that IL-6 is not high or in HLH /macrophage activation syndrome. However, due to elevated TNFα in SARS-CoV, the use of TNFα inhibitors has a potential role to suppress the inflammatory cascade and ameliorating the severe alveolar damage. Also, these groups can modulate biological responses that are mediated by TNF or even induce immunosuppressive Treg cells (especially Adalimumab). Nevertheless, there is no evidence indicating that TNFα inhibition is harmful in COVID-19 patients, and also there is no strong evidence for their use. Studies utilizing TNFα blockers for COVID-19 would be prudent. Although JAK or tyrosine kinase inhibitors could reduce viral infectivity, viral replication, and the aberrant host inflammatory state historically, further studies are required to confirm their therapeutic effects.

Conclusion
Despite the collective wisdom, decision-making regarding the management of COVID-19 especially in severe conditions is a challenging problem. Although several anti-inflammatory and immunomodulatory drugs are candidates, their definite effects are unknown. The results for repurposing therapies are contradictory allowing humans to make several choices. Although cytokine suppression seems essential in cytokine storm as a possible way to save the patient’s life, this method in non-hyper-inflammatory conditions may endanger the patient’s life. The timing of treatment is also important. Low-dose steroids may be effective in the early phases of illness, IVIG may be served to deteriorating patients or to block antibodies and immune complexes elsewhere. Moreover, tocilizumab is more effective in severe situations when the IL-6 level is high and other drugs are ineffective. We suggest that decisions should be taken for each patient, separately. However, more studies are needed to decipher the therapeutic secrets of this dilemma.

Acknowledgments
The authors thank the staff and participants of this study for their important contributions.

Author Contribution
RS: Substantial contributions to the conception and design of the study; acquisition, analysis, revising the manuscript critically for important intellectual content, and interpretation of data, drafting the manuscript, final approval of the version to be published. SP: Acquisition and interpretation of data, revising the manuscript critically for important intellectual content, final approval of the version to be published. AA: Acquisition and interpretation of data, revising the manuscript critically for important intellectual content, final approval of the version to be published. RS: Acquisition and interpretation of data, revising the manuscript critically for important intellectual content, final approval of the version to be published. AS: Acquisition and interpretation of data, revising the manuscript critically for important intellectual content, final approval of the version to be published.

Conflict of Interest
The authors did not report any (financial or otherwise) conflict of interest.

Supplementary Data
Tables S1-S8 are available on the journal’s web site along with the published article.

References
1. Sinaei R, Pezeshki S, Parvaresh S, Sinaei R. Why COVID-19 is less frequent and severe in children: a narrative review. World J Pediatr. 2020;17(1):10-20. doi:10.1007/s12519-020-00392-y
2. Sinaei R, Hosseininasab A, Jafari M, Eslami S, Parvaresh S. The multi-system inflammatory syndrome of childhood (MIS-C). Indian J Pediatr. 2021;88(5):484. doi:10.1007/s12098-020-03617-0
3. Hosseininasab A, Sinaei R, Bahman-Bijari B,
The Rheumatic Drugs against COVID-19

Moinealdini R. Nasal colonization rate of community and hospital acquired methicillin resistant Staphylococcus aureus in hospitalized children. J Kerman Univ Med Sci. 2013;20(1):52-62. Persian.

4. Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020;181(4):905-13. doi:10.1016/j.cell.2020.04.004

5. Zhao J, He S, Minassian A, Li J, Peng P. Recent advances on viral manipulation of NF-κB signaling pathway. Curr Opin Virol. 2015;10:103-11. doi:10.1016/j.coovi.2015.08.013

6. Caricchio R, Gallucci M, Dass C, Zhang X, Gallucci S, Fleece D, et al. Preliminary predictive criteria for COVID-19 cytokine storm. Ann Rheum Dis. 2021;80:88-95. doi:10.1136/annrheumdis-2020-218323

7. Cure E, Kucuk A, Cure MC. Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19). Rheumatol Int. 2020. doi:10.1007/s00296-020-04603-7

8. Nicolai L, Leunig A, Brambs S, Kaiser R, Weinberger T, Weigand M, et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation. 2020;142(12):1176-89. doi:10.1161/CIRCULATIONAHA.120.048488

9. Monti S, Balduzzi S, Delvino P, Bellis E, Quadralli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79(5):667-8. doi:10.1136/annrheumdis-2020-217424

10. Hassas Yeganeh M, Talaei M, Bazzaz AE, Rahmani K, Sinaei R, Fathi M, et al. Determination of diagnostic value (validity) leukocyte esterase (urine dipstick strip) in differentiating inflammatory arthritis from bacterial arthritis. Adv Rheumatol 2020;60(1):11. doi:10.1186/s43258-020-0115-3

11. Critical Appraisal Tools. Critical-appraisal-tools - Critical Appraisal Tools | Joanna Briggs Institute (jbi.global). Accessed 28 February 2021.

12. Study Quality Assessment Tools. https://www.nlm.nih.gov/health-topics/study-quality-assessment-tools. Accessed 28 February 2021.

13. Becker M, Lovell D, Leeder J, Chapter on Pharmacology. In: Petty R, Laxer R, Lindsley C, Wedderburn L, editors. Textbook of Pediatric Rheumatology 7ed. Amsterdam: Elsevier; 2016.

14. Hassas Yeganeh M, Zafari N, Sardarinia M, Mahboubi L, Parvaneh VJ, Salehi S, et al. Autoimmune hepatitis as an initial presentation of SLE. Arch Pediatr Infect Dis. 2016;4(3):e34653. doi:10.5812/pedinfec.t.34653

15. Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020;145:104228. doi:10.1016/j.micpath.2020.104228

16. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis. 2003;3(11):722-7. doi:10.1016/s1473-3099(03)00806-5

17. Arya R, Das A, Prashar V, Kumar M. Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs. ChemRxiv. Cambridge: Cambridge Open Engage; 2020. doi:10.26434/chemrxiv

18. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-71. doi:10.1038/s41422-020-0282-0

19. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6(1):16. doi:10.1038/s41421-020-0156-0

20. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732-9. doi:10.1093/cid/ciaa237

21. Chen L, Zhang Z-Y, Fu J-G, Feng Z-P, Zhang S-Z, Han Q-Y, et al. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study. medRxiv. 2020. doi:10.1101/2020.06.19.20136093

22. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-3. doi:10.5582/bst.2020.01047

23. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020. doi:10.1101/2020.03.22.20040758

24. Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. Treating COVID-19 with chloroquine. J Mol Cell Biol. 2020;12(4):322-5. doi:10.1093/jmcb/mjaa014

25. Yu B, Wang DW, Li C. Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. medRxiv. 2020. doi:10.1101/2020.04.27.20073379

26. Gautret P, Lagier J-C, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment for COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi:10.1016/j.ijantimicag.2020.105949

27. Gautret P, Lagier J-C, Parola P, Meddeb L, Sevestre J, Mailhe M, et al. Clinical and microbiological effect of a
combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow-up: A pilot observational study. Travel Med Infect Dis, 2020;34:101663. doi: 10.1016/j.tmaid.2020.101663

28. Magagnoli J, Narendran S, Pereira F, Cummings TH, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. Med (N Y). 2020;1(1):114-27. doi:10.1016/j.med.2020.06.001

29. Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huising K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396-403. doi:10.1016/j.ijid.2020.06.099

30. Million M, Lagier J, Gautret P, Colson P, Fournier P, Amrane S, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;35:101738. doi:10.1016/j.tmaid.2020.101738

31. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with inhospital mortality in patients with COVID-19 in New York state. JAMA 2020;323(24):2493-2502. doi:10.1001/jama.2020.8630

32. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020;382(25):2411-8. doi:10.1056/NEJMoa2012410

33. Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclaire BA, et al. Hydroxychloroquine and tocilizumab therapy in covid-19 patients-an observational study. PLoS One. 2020;15(8):e0237693. doi:10.1371/journal.pone.0237693

34. Molina JM, Delaquerre C, Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50(4):384. doi:10.1016/j.medmal.2020.03.006

35. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020;369:m1849. doi:10.1136/bmj.m1849

36. Sbidian E, Josse J, Lemaitre G, Mayer I, Bernaux M, Gramfort A, et al. Hydroxychloroquine with or without azithromycin in and hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France. medRxiv. 2020. doi:10.1101/2020.06.16.20132597

37. Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:m1844. doi:10.1136/bmj.m1844

38. Singh S, Khan A, Chowdhry M, Chatterjee A. Outcomes of hydroxychloroquine treatment among hospitalized covid-19 patients in the united states-real-world evidence from a federated electronic medical record network. medRxiv. 2020. doi:10.1101/2020.05.12.20099028

39. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LC, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19. N Engl J Med. 2020;383(21):e119. doi:10.1056/NEJMoa2019014

40. Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Logfren SM, et al. Hydroxychloroquine in nonhospitalized adults with early covid-19: A randomized trial. Ann Intern Med. 2020;173(8):623-31. doi:10.7326/M20-4207

41. Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19: a quasi-randomized comparative study. https://aslm.org/resource/clinical-outcomes-of-hydroxychloroquine-in-hospitalized-patients-with-covid-19. Accessed 28 February 2021.

42. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857-e. doi:10.1001/jamanetworkopen.2020.8857

43. Mallat J, Hamed F, Balkis M, Mohamed MA, Mooty M, Malik A, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study. medRxiv. 2020. doi:10.1101/2020.04.27.20082180

44. De Novales FJM, Ramírez-Olivencia G, Estébanez M, de Dios B, Herrero MD, Mata T, et al. Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study. Preprints. 20202020050057. doi:10.20944/preprints202005.0057v1

45. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. [A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)]. J Zhejiang Univ. 2020;49(2):215-9. Chinese. doi:10.3785/j.issn.1008-9292.2020.03.03

46. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Logfren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383:517-25. doi:10.1056/NEJMoa2016638

47. Peiris JSM, Chu C-M, Cheng VC-C, Chan K, Hung I, Poon LL, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.
Lancet. 2003;361(9371):1767-72. doi: 10.1016/S0140-6736(03)13412-5

48. Zhang X, Alekseev K, Jung K, Vlasova A, Hadya N, Saif LJ. Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome. J Virol. 2008;82(9):4420-8. doi: 10.1128/JVI.02190-07

49. Wong C, Lam C, Wu A, Ip W, Lee N, Chan I, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95-103. doi: 10.1111/j.1365-2249.2004.02415.x

50. Chen R-C, Tang X-P, Tan S-Y, Liang B-L, Wan Z-Y, Fang J-Q, et al. Treatment of severe acute respiratory syndrome with glucocorticoids: The Guangzhou experience. Chest. 2006;129(6):1441-52. doi: 10.1378/chest.129.6.1441

51. Jian-ya G. Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing, China. medRxiv. 2020. doi: 10.1101/2020.02.20.20025536

52. Qin X, Qiu S, Yuan Y, Zong Y, Tuo Z, Li J, et al. Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China. SSRN. 2020. doi: 10.2139/ssrn.3541147

53. Yang SS, Lipes J. Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series. Can J Anaesth. 2020. doi: 10.1007/s12630-020-01700-w

54. Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv. 2020. doi: 10.1101/2020.03.06.20032342

55. Zha L, Li S, Pan L, Tefsen B, Li Y, French N, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212(9):416-20. doi: 10.5694/mja2.50577

56. Zhou Z-G, Xie S-M, Zhang J, Zheng F, Jiang D-X, Li K-Y, et al. Short-term moderate-dose corticosteroid plus immunoglobulin effectively reverses covid-19 patients who have failed low-dose therapy. Preprints. 2020;2020030065. doi: 10.20944/preprints202003.0065.v1

57. Fadel R, Morrison A, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, et al. Early short course corticosteroids in hospitalized patients with COVID-19. medRxiv. 2020. doi: 10.1101/2020.05.04.20074609

58. Corral L, Bahamonde A, delas Revillas FA, Gomez-Barquero J, Abadía-Otero J, García-Ibarbia C, et al. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. medRxiv. 2020. doi: 10.1101/2020.06.17.20133579

59. Horby P, Lim WS, Emberson J, Malham M, Bell J, Linsell L, et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv. 2020. doi: 10.1101/2020.06.22.20137273

60. Liu J, Zheng X, Huang Y, Shan H, Huang J. Successful use of methylprednisolone for treating severe COVID-19. J Allergy Clin Immunol. 2020;146(2):325-7. doi: 10.1161/j.jaci.2020.05.021

61. Marla JK, Elizabeth AK, MBE SA, Jen-Ting C, MS SA, Michael JR, et al. Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients with COVID-19. J Hosp Med. 2020;8:489-93. doi: 10.12788/jhm.3497

62. Shang J, Du R, Lu Q, Wu J, Xu S, Ke Z, et al. The treatment and outcomes of patients with COVID-19 in Hubei, China: a multi-centered, retrospective, observational study. SSRN. 2020. doi: 10.2139/ssrn.3546060

63. So C, Ro S, Murakami M, Imai R, Jinta T. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series. Respiri Case Rep. 2020;8(6):e00596. doi: 10.1016/j.rccr.596

64. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020;382(21):2012-22 doi: 10.1056/NEJMoA2004500

65. Zhang Z, Li X, Zhang W, Shi Z-L, Zheng Z, Wang T. Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: report of a couple cases. Virol Sin. 2020;35(3):330-6. doi: 10.1007/s12250-020-00203-8

66. Chen C, Qi F, Shi K, Li Y, Li J, Chen Y, et al. Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 pneumonia. Clin Transl Med. 2020;10(2)e35. doi: 10.1002/ctm2.35

67. Dai J, Xiong Y, Li H, Qian Y, Xu Y, Xu Q, et al. Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review. Clin Rheumatol. 2020;39:2031-2037. doi: 10.1007/s10067-020-05172-7

68. Bancos S, Bernard MP, Topham DJ, Phipps RP. Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cell Immunol. 2009; 258(1):18-28. doi: 10.1016/j.cellimm.2009.03.007

69. Amici C, Di Coro A, Giucci A, Chiappa L, Castilli C, Martella V, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir Ther, 2006;11(8):1021-30.

70. Arai I, Mao G-P, Otani K, Konno S, Kikuchi S, Oelz O, Frolich JC, Seyberth HW, Martella V, et al. Indomethacin blocks the nucleus pulposus-induced effects on nerve root function. Eur Spine J. 2004;13(8):691-4. doi: 10.1016/j.spinee.2002.08.014

71. Rane A, Oelz O, Frolich JC, Seyberth HW, Sweetman BJ, Watson JT, et al. Relation between plasma inflammatory cytokines and chemokines in patients with COVID-19. J Rheumatol. 1978;23(6):658-68.
72. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020;35(3):266-71. doi:10.1007/s12250-020-00207-4

73. Fang L, Karakulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-8

74. Day M. Covid-19: ibuprofen should not be used for managing symptoms, says doctors and scientists. BMJ. 2020;368:m1086. doi:10.1136/bmj.m1086

75. Kotsiou OS, Zarogiannis SG, Gourgoulouianis KI. Prehospital NSAIIDs use prolong hospitalization in patients with pleuro-pulmonary infection. Respir Med. 2017;123:28-33. doi:10.1016/j.rmed.2016.12.005

76. Le Bourgeois M, Ferroni A, Leruez-Ville M, Varon E, Thumereille C, Brémont F, et al. Nonsteroidal anti-inflammatory drug without antibiotics for acute viral infection increases the empyema risk in children: a matched case-control study. J Pediatr. 2016;175:47-53. doi:10.1016/j.jpeds.2016.05.025

77. Hada M. Chemotherapeutic Strategy with Sibnytics, Thalidomide and Colecobix for severe COVID-19 Pneumonia. Association between microbiota, chronic inflammation and pneumonia. 2020. doi:10.13140/RG.2.2.26979.91689. Available at: https://www.scienceopen.com/document?vid=44bda6e4-7857-4d77-a102-7c6b51baaa86

78. Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 2020;26(9):1259.e5-7. doi:10.1016/j.cmi.2020.06.003

79. Kragholm K, Gerds TA, Fosbol E, Andersen MP, Phelps M, Butt JH, et al. Association between ibuprofen exposure and severe COVID-19 infection: a nationwide register-based study. 2020;13(6):1103-7. doi:10.1016/j.cmi.2020.06.003

80. Jeong HE, Lee H, Shin HJ, Choi YJ, Filipion KB, Shin JY. Association between NSAIIDs use and adverse clinical outcomes among adults hospitalised with COVID-19 in South Korea: A nationwide study. medRxiv. 2020. doi:10.1093/cid/ciaa1056

81. Dastan F, Tabarsi P, Marjani M, Moniri A, Hashemian SM, Tavakoli-Ardakani M, et al. Thalidomide against coronavirus disease 2019 (covid-19): A medicine with a thousand faces. Iran J Pharm Res. 2020;19(1):1-2. doi:10.22037/IJPR.2020.113369.14259

82. Tabata C, Tabata R, Takahashi Y, Nakamura K, Nakano T. Thalidomide prevents cigarette smoke extract-induced lung damage in mice. Int Immunopharmacol. 2015;25(2):511-7. doi:10.1016/j.intimp.2015.02.036

83. Moreira AL, Corral LG, Ye W, Johnson B, Stirling D, Muller GW, et al. Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses. 1997;13(10):857-63. doi:10.1089/aid.1997.13.857

84. Amirshahrokhi K. Anti-inflammatory effect of thalidomide in paraquat-induced pulmonary injury in mice. Int Immunopharmacol. 2013;17(2):210-5. doi:10.1016/j.intimp.2013.06.005

85. Dong X, Li X, Li M, Chen M, Fan Q, Wei W. Anti-inflammation and antioxidant effects of thalidomide on pulmonary fibrosis in mice and human lung fibroblasts. Inflammation 2017;40(6):1836-46. doi:10.1007/s10753-017-0625-2

86. Dong X, Li X, Li M, Chen M, Fan Q, Wei W. Inhibitory effects of thalidomide on bleomycin-induced pulmonary fibrosis in rats via regulation of thioredoxin reductase and inflammations. Am J Transl Res. 2017;9(10):4390-401.

87. Zhu H, Shi X, Ju D, Huang W, Wei W, Dong X. Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice. Inflammation. 2014;37(6):2091-8. doi:10.1007/s10753-014-9943-9

88. De Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, Thiel V, Narayanan K, Makino S, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. 2011;92(Pt 11):2542-8. doi:10.1099/vir.0.034983-0

89. Luo C, Luo H, Zheng S, Gui C, Yue L, Yu C, et al. Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A. Biochem Biophys Res Commun. 2004;321(3):557-65. doi:10.1016/j.bbrc.2004.07.003

90. Te Velthuis AJ, Arnold JJ, Cameron CE, van den Worm SH, Snijder EJ. The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent. Nucleic Acids Res. 2010;38(1):203-14. doi:10.1093/nar/gkp904

91. Briggs C, Ott D, Coren L, Oroszlán S, Tőzsér J. Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1. Arch Virol. 1999;144(11):2151-60. doi:10.1007/s007050050629

92. Bose S, Mathur M, Bates P, Joshi N, Banerjee AK. Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype. J Gen Virol. 2003;84(7):1687-99. doi:10.1099/vir.0.034983-0

93. Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Viral. 1999;84(7):1687-99. doi:10.1099/vir.0.034983-0

94. Briggs C, Ott D, Coren L, Oroszlán S, Tőzsér J. Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1. Arch Virol. 1999;144(11):2151-60. doi:10.1007/s007050050629

95. Ma C, Li F, Musharrafieh RG, Wang J. Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance. Antiviral Res. 2010;3(3):225-32. doi:10.1016/j.antiviral.2010.07.019

96. Llowite NT, Laxer RM. Pharmacology: Biologics. In: Petty RE, Laxer RM, Lindsay CB, Wedderburn L, editors. Textbook of pediatric rheumatology. 7 ed. Amsterdam: Elsevier Health Sciences; 2015.
characterization and infectivity of a novel SARS-like coronavirus in Chinese bats. Emerg Microbes Infect. 2018;7:54. doi:10.1038/s41426-018-0155-5

97. Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, Rager-Zisman B. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis. 2003;188(1):5-12. doi:10.1086/376870

98. Pyrc K, Bosch BJ, Berkhout B, Jebbink MF, Dijkman R, Rottier P, et al. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother. 2006;50(6):2000-8. doi:10.1128/AAC.01598-05

99. Boukhvalova M, Blanco J, Falsey A, Mond J. Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus. Bone Marrow Transplant. 2016;51(1):119-26. doi:10.1038/bmt.2015.212

100. Charlet R, Sendib D, Kaveri SV, Poulain D, Bayry J, Jawhara S. Intravenous Immunoglobulin Therapy Eliminates Candida albicans and Maintains Intestinal Homeostasis in a Murine Model of Dextran Sulfate Sodium-Induced Colitis. Int J Mol Sci. 2019;20(6):1473. doi:10.3390/ijms20061473

101. Wang J-T, Sheng W-H, Fang C-T, Chen Y-C, Wang J-L, Yu C-J, et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis. 2004;10(5):818-24. doi:10.3201/eid1005.030640

102. Arabi YM, Arif AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160(6):389-97. doi:10.7326/M13-2486

103. Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. editors. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. Open Forum Infectious Diseases. Oxford: Oxford University Press US; 2020. doi:10.1093/ofid/ofaa102

104. Shao Z, Feng Y, Zhong L, Xie Q, Lei M, Liu Z, et al. Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A multicenter retrospective cohort study. Clin Transl Immunology. 2020;9(10):e1192. doi:10.1002/cti2.1192

105. Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020;81(2):318-56. doi:10.1016/j.jinf.2020.03.044

106. Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against covid-19 and strengthen the immune system of new patients? Int J Mol Sci. 2020;21(7):2272. doi:10.3390/ijms21072272

107. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci. 2020;117(20):10970-5. doi:10.1073/pnas.2005615117

108. Levi M. Tocilizumab for severe COVID-19: a promising intervention affecting inflammation and coagulation. Eur J Intern Med. 2020;76:21-22. doi:10.1016/j.ejim.2020.05.018

109. Chen L, Liu H, Liu W, Liu J, Liu K, Shang J, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E005-E. doi:10.3760/cma.j.issn.1001-0939.2020.0005

110. Ishii K, Hasegawa H, Nagata N, Ami Y, Fukushima S, Taguchi F, et al. Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model. Microbiol Immunol 2009;53(2):75-82. doi:10.1111/j.1348-0421.2008.00097.x

111. Sheng W-H, Chiang B-L, Chang S-C, Ho H-N, Wang J-T, Chen Y-C, et al. Clinical manifestations and inflammatory cytokine responses in patients with severe acute respiratory syndrome. J Formos Med Assoc. 2005;104(10):715-23.

112. Lau SK, Lau CC, Chan K-H, Li CP, Chen H, Jin D-Y, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Virol. 2013;94(12):2679-90. doi:10.1128/jvi.005533-0

113. Lucena-Silva N, Torres LC, Luna CF, de Barros Correia J, da Silva GAP. The balance between the serum levels of IL-6 and IL-10 cytokines discriminates mild and severe acute pneumonia. BMC Pulm Med. 2016;16(1):170. doi:10.1186/s12890-016-0324-z

114. Mahmud-Al-Rafat A, Majumder A, Rahman KT, Hasan AM, Islam KD, Taylor-Robinson AW, et al. Decoding the enigma of antiviral crisis: Does one target molecule regulate all? Cytokine 2019;115:13-23.

115. Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E005-E.
with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020;79(10):1277-85. doi:10.1136/annrheumdis-2020-218122

119. Montesarchio V, Parea R, Iommelli C, Bianco A, Manzillo E, Fraganza F, et al. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer. 2020;8(2):e001089. doi:10.23007/jitc-2020-001089

120. Benucci M, Giannasi G, Cecchini P, Gobbi FL, Damiani A, Grossi V, et al. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients. J Med Virol. 2020;92(11):2368-70. doi:10.1002/jmv.26062

121. Gremese E, Cingolani A, Bosello SL, Aliverinni S, Toluso B, Perniola S, et al. Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine. 2020;27:100553. doi:10.1016/j.eclinm.2020.100553

122. Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19. Clin Exp Rheumatol. 2020;38(3):529-32.

123. Toniati P, Piva S, Cattalini M, Garrafà E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. doi:10.1016/j.autrev.2020.102568

124. Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua R, et al. Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes. Chest. 2020;158(4):1397-408. doi:10.1016/j.chest.2020.06.006

125. Jordan SC, Zakowski P, Tran HP, Smith EA, Gaultier C, Marks G, et al. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia. Clin Infect Dis. 2020;71(12):3168-73. doi:10.1093/cid/ciaa812

126. Morena V, Milazzo L, Oreni L, Bestetti G, Fossali T, Bassoli C, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med. 2020;76:31-5. doi:10.1016/j.ejim.2020.05.009

127. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;92(7):814-8. doi:10.1002/jmv.25801

128. Garcia EM, Caballero VR, Albiach L, Aguero D, Ambrosioni J, Bodro M, et al. Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. medRxiv. 2020. doi:10.1101/2020.06.05.20113738

129. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474-84. doi:10.1016/S2665-9913(20)30173-9

130. Kewan T, Covut F, Al-Jaghebeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. E ClinicalMedicine. 2020;2(8):e474-84. doi:10.1016/j.eclinm.2020.100418

131. Altattar R, Ibrahim TB, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. Tocilizumab for the treatment of severe COVID-19. J Med Virol. 2020;92(10):2042-9. doi:10.1002/jmv.25964

132. Keske Ş, Tekin S, Sait B, İrkören P, Kapmaz M, Çimen C, et al. Appropriate use of tocilizumab in COVID-19 infection. Int J Infec Dis. 2020;99:338-43. doi:10.1016/j.ijid.2020.07.036

133. Tomasiewicz K, Piekarska A, Stempskowska-Rejek J, Serafinska S, Gawkowska A, Parczewski M, et al. Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study. Expert Rev Anti Infect Ther. 2020;19(1):93-100. doi:10.1080/14787210.2020.1800453

134. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. medRxiv. 2020. doi:10.1101/2020.05.29.20117358

135. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020;76:31-5. doi:10.1016/j.ejim.2020.05.009

136. Petrak R, Skorodonin N, Van Hise N, Fliegelman R, Pinsky J, Didwania V, et al. Tocilizumab as a therapeutic agent for critically ill patients infected with SARS-CoV-2. Clin Transl Sci. 2020. doi:10.1111/cts.12894

137. Martinez-Sanz J, Muriel A, Ron R, Herrera S, Perez-Molina JA, Moreno S, et al. Effects of tocilizumab on mortality in hospitalized patients with covid-19: a multicenter cohort study. Clin Microbiol Infect. 2021;27(2):238-43. doi:10.1016/j.cmi.2020.09.021

138. Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F, et al. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMA勃勃COVID19 Registry (SMACORE). Microorganisms. 2020;8(5):695. doi:10.3390/microorganisms8050695

139. Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43-9. doi:10.1016/j.ejim.2020.05.021

140. Emilio P, Carl OD. Roche rheumatoid arthritis drug fails to help COVID-19 patients in Italian study: Reuters; 2020. Available from: https://www.reuters.com/article/us-health-coronavirus-roche-hldg/roche-rheumatoid-arthritis-drug-fails-to-help-covid-19-patients-in-italian-study-idUSKBN23O3GG

141. Marfella R, Paolisso P, Sardu C, Bergamaschi L, D’Angelo EC, Barbieri M, et al. Negative impact of hyperglycaemia on tocilizumab therapy in
The Rheumatic Drugs against COVID-19

142. Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4(7):1307. doi:10.1182/bloodadvances.2020001907

143. Michot J-M, Albignes L, Chaput N, Saada V, Pommeret F, Griscelli F, et al. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol 2020;31(7):961-4. doi:10.1016/j.annonc.2020.03.290

144. Wang L, Peng X, Wang Z, Cai J, Zhou F. Tocilizumab in the treatment of a critical COVID-19 patient: a case report. Eur Rev Med Pharmacol Sci 2020;24(10):5783-7. doi:10.26355/eurrev_202005_21372

145. Cascella M, Mauro I, De Blasio E, Crispo A, Del Gaudio A, Bimoto S, et al. Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS. Medicina. 2020;56(8):377. doi:10.3390/medicina56080377

146. Uslu S. Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome. Eur J Case Rep Intern Med. 2020;7(6):001731. doi:10.12890/2020_001731

147. Ferrey AJ, Choi G, Hanna RM, Chang Y, Tantisattamo E, Ivaturi K, et al. A case of novel coronavirus disease 19 in a chronic hemodialysis patient presenting with gastroenteritis and developing severe pulmonary disease. Am J Nephrol. 2020;51(5):337-42. doi:10.1159/000507417

148. Melody M, Nelson J, Hastings J, Propst J, Smerina M, Mendez J, et al. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019. Immunotherapy. 2020;12(15):1121-6. doi:10.2217/imt-2020-0136

149. Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report. Chest. 2020;158(1):e15-9. doi:10.1016/j.chest.2020.04.024

150. Mihai C, Dobrota R, Schröder M, Garaiman A, Jordan A, Becker MO, et al. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis. 2020;79(5):668-9. doi:10.1136/annrheumdis-2020-217442

151. Miura TA, Wang J, Holmes KV, Mason RJ. Rat coronaviruses infect rat alveolar type I epithelial cells and induce expression of CXC chemokines. Virology. 2007;369(2):288-98. doi:10.1016/j.virol.2007.07.030

152. Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393-400. doi:10.1016/S2665-9913(20)30164-8

153. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325-31. doi:10.1016/S2665-9913(20)30127-2

154. Navarro-Millán I, Sattui SE, Lakhanpal A, Zisa D, Siegel CH, Crow MK. Use of anakinra to prevent mechanical ventilation in severe COVID-19: A Case Series. Arthritis Rheumatol. 2020;72(12):1990-1997. doi:10.1002/art.41422

155. Dimopoulos G, de Mast Q, Markou N, Theodorakopoulou M, Konnoss A, Moukotoreu M, et al. Favorable anakinra responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe. 2020;28(1):117-23. doi:10.1016/j.chom.2020.05.007

156. Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis. 2020;79(10):1381-2. doi:10.1136/annrheumdis-2020-217706

157. Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, Blasco VB, et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc Natl Acad Sci U S A. 2020;117(32):18951-3. doi:10.1073/pnas.2009017117

158. Franzetti M, Pozzetti U, Carugati M, Pandolfo A, Molteni C, Facchioni P, et al. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report. Int J Infec Dis. 2020;97:215-8. doi:10.1016/j.ijid.2020.05.050

159. Filocamo G, Mangioni D, Tagliabue P, Aliberti S, Costantino G, Minoa F, et al. Use of anakinra in severe COVID-19: A case report. Int J Infec Dis. 2020;96:607-9. doi:10.1016/j.ijid.2020.05.026

160. González-García A, García-Sánchez I, Lopes V, Moreno-Arroces OM, Tortosa-Cabañas M, Elías-Sáenz I, et al. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment. Rheumatology. 2020;59(8):2171-3. doi:10.1093/rheumatology/keaa318

161. Karadeniz H, Yamak BA, Özger HS, Senezöz B, Tufan A, Emmi G. Successful use of anakinra in a patient with COVID-19-associated pericarditis. Res Sq. 2020. doi:10.21203/rs.3.rs-35779/v1

162. Ucciferri C, Auricchio A, Di Nicola M, Potere N, Abbate A, Cipollone F, et al. Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatol. 2020;2(8):e457-8. doi:10.1016/j.rheum.2020.05.007

163. Li H, Liu H. Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19. J Allergy Clin Immunol. 2020;146(6):1453. doi:10.1016/j.jaci.2020.09.002
164. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (London, England) 2020;395(10223):e30-1. doi:10.1016/S0140-6736(20)30304-4

165. Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020;146(1):137-46. doi:10.1016/j.jaci.2020.05.019

166. Giudice V, Pagliano P, Vatrella A, Masullo A, Poto S, Polverino BM, et al. Combination of ruxolitinib and eculizumab for treatment of severe sars-cov-2-related acute respiratory distress syndrome: a controlled study. Front Pharmacol. 2020;11:857. doi:10.3389/fphar.2020.00857

167. Cantini F, Niccoli L, Nannini C, Matarrese D, Di Natale ME, Lotti P, et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect. 2020; 81(4):647-79. doi:10.1016/j.jinf.2020.06.052

168. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;81(2):318-56. doi:10.1016/j.jinf.2020.04.017

169. Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. Covid-19 in immune-mediated inflammatory diseases—case series from New York. N Engl J Med. 2020;383(1):85-8. doi:10.1056/NEJMc2009567

170. Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Canè S, et al. Baricitinib restrains the immune dysregulation in COVID-19 patients. medRxiv. 2020. doi:10.1101/2020.06.26.20135319

171. Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribs SK, et al. use of baricitinib in patients with moderate and severe covid-19. Clin Infect Dis. 2020;72(7):1247-50. doi:10.1093/cid/ciaa879

172. Bosch-Barrera J, Martin-Castillo B, Buxó M, Brunet J, Encinar JA, Menendez JA. Silibinin and sars-cov-2: dual targeting of host cytokine storm and virus replication machinery for clinical management of covid-19 patients. J Clin Med. 2020;9(6):1770. doi:10.3390/jcm9061770

173. Sodani P, Mucci L, Girolimetti R, Tedesco S, Monaco F, Campanozzi D, et al. Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis. Respir Med Case Rep. 2020;31:101115. doi:10.1016/j.rmrcc.2020.101115

174. Cingolani A, Tummolo A, Montemurro G, Gremese E, Larosa L, Cipriani M, et al. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. Infection. 202:48(5):767-71. doi:10.1015/s1050-020-01476-7

175. Lo Caputo S, Corso G, Clerici M, Santantonio TA. Baricitinib: a chance to treat COVID-19? J Med Virol. 2020;92(11):2343-4. doi:10.1002/jmv.26033

176. Hussell T, Pennycook A, Openshaw PJ. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol. 2001;31(9):2566-73. doi:10.1002/1521-4141(200109)31:9<2566::aid-immu2566>3.0.co;2-1

177. Yanik G, Hellerstedt B, Custer J, Hutchinson R, Kwon D, Ferrara JL, et al. Etaercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8(7):395-400. doi:10.1053/bbmt.2002.v8.pm12171486